MD357Z - Method for predicting the risk of hematogenic metastasis after treatment of neoplasia of the neck of uterus - Google Patents
Method for predicting the risk of hematogenic metastasis after treatment of neoplasia of the neck of uterus Download PDFInfo
- Publication number
- MD357Z MD357Z MDS20110006A MDS20110006A MD357Z MD 357 Z MD357 Z MD 357Z MD S20110006 A MDS20110006 A MD S20110006A MD S20110006 A MDS20110006 A MD S20110006A MD 357 Z MD357 Z MD 357Z
- Authority
- MD
- Moldova
- Prior art keywords
- risk
- staining
- hematogenic
- metastasis
- neoplasia
- Prior art date
Links
- 206010027476 Metastases Diseases 0.000 title abstract 4
- 230000002324 hematogenic effect Effects 0.000 title abstract 4
- 230000009401 metastasis Effects 0.000 title abstract 4
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 230000009826 neoplastic cell growth Effects 0.000 title abstract 2
- 210000004291 uterus Anatomy 0.000 title abstract 2
- 238000010186 staining Methods 0.000 abstract 3
- 102000007469 Actins Human genes 0.000 abstract 2
- 108010085238 Actins Proteins 0.000 abstract 2
- 230000001900 immune effect Effects 0.000 abstract 2
- 210000002460 smooth muscle Anatomy 0.000 abstract 2
- 238000001574 biopsy Methods 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 abstract 1
- 238000012137 double-staining Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 210000003989 endothelium vascular Anatomy 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 210000000663 muscle cell Anatomy 0.000 abstract 1
- 230000000771 oncological effect Effects 0.000 abstract 1
- 210000003668 pericyte Anatomy 0.000 abstract 1
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The invention relates to medicine, in particular to oncologic morphopathology and can be used for predicting the risk of hematogenic metastasis after treatment of neoplasia of the neck of uterus using the immunological double staining with monoclonal antibodies anti-CD31 and anti-α smooth muscle actin.Summary of the invention consists in that there are prepared histological sections from biopsy materials of a thickness of 3 µm, they are stained with hematoxylin-eosin, and then there are carried out the reactions of immunological staining with monoclonal antibody anti-CD31, clone IC70A, with staining in brown of vascular endothelium, afterwards with the monoclonal antibody anti-α smooth muscle actin, clone 1A4, with staining in red of perivascular muscle cells and pericytes, on the basis of which is determined the number of immature vessels and if it is determined up to 5 immature vessels, it is predicted a minor risk of hematogenic metastasis, and if more than 5 immature vessels, it is predicted an increased risk of hematogenic metastasis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MDS20110006A MD357Z (en) | 2011-01-03 | 2011-01-03 | Method for predicting the risk of hematogenic metastasis after treatment of neoplasia of the neck of uterus |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MDS20110006A MD357Z (en) | 2011-01-03 | 2011-01-03 | Method for predicting the risk of hematogenic metastasis after treatment of neoplasia of the neck of uterus |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MD357Y MD357Y (en) | 2011-04-30 |
| MD357Z true MD357Z (en) | 2011-11-30 |
Family
ID=45815103
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MDS20110006A MD357Z (en) | 2011-01-03 | 2011-01-03 | Method for predicting the risk of hematogenic metastasis after treatment of neoplasia of the neck of uterus |
Country Status (1)
| Country | Link |
|---|---|
| MD (1) | MD357Z (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2489718C1 (en) * | 2012-06-22 | 2013-08-10 | Федеральное государственное бюджетное учреждение "Научно-исследовательский институт онкологии" Сибирского отделения Российской академии медицинских наук (ФГБУ "НИИ онкологии" СО РАМН) | Method for prediction of onset of hematogenous metastases accompanying squamous cell lung cancer |
-
2011
- 2011-01-03 MD MDS20110006A patent/MD357Z/en not_active IP Right Cessation
Non-Patent Citations (2)
| Title |
|---|
| Hoskins W.J. Prognostic factors for risk of recurrence in stages Ib and IIa cervical cancer. Baillieres Clin Obstet. Gynaecol. 1988, №4, p. * |
| Hoskins W.J. Prognostic factors for risk of recurrence in stages Ib and IIa cervical cancer. Baillieres Clin Obstet. Gynaecol., 1988, №4, p. 817-828 * |
Also Published As
| Publication number | Publication date |
|---|---|
| MD357Y (en) | 2011-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR106184A1 (en) | PD-1 BINDING PROTEINS AND THEIR METHODS OF USE | |
| NZ716369A (en) | Anti-ox40 antibodies and methods of using the same | |
| JOP20180042A1 (en) | Humanized Antigen-Binding Domains and Methods of Use | |
| AR072167A1 (en) | ANTIBODIES AGAINST HUMAN IL-6 AND ITS USES | |
| WO2013037484A3 (en) | Anti-aplhabetatcr antibody | |
| EP3991748A3 (en) | Anti-sortilin antibodies and methods of use thereof | |
| WO2017062672A3 (en) | Anti-trem2 antibodies and methods of use thereof | |
| WO2014035693A3 (en) | Methods and compositions related to modulators of eukaryotic cells | |
| WO2014012085A3 (en) | Bispecific asymmetric heterodimers comprising anti-cd3 constructs | |
| WO2013188864A3 (en) | Anti-cd22 anti-idiotypic antibodies and uses thereof | |
| WO2013004076A8 (en) | Agr2 blocking antibody and use thereof | |
| CL2007003479A1 (en) | Human anti-cd22 monoclonal antibody or an antigen-binding fragment thereof; nucleic acid, vector, host cell; Preparation method; composition; immunoconjugate; and its use to inhibit the growth of a tumor or treat an inflammatory or autoimmune disorder in a subject. | |
| HRP20200034T1 (en) | MONOCLONE ANTIBODIES AGAINST GROWTH AND DIFFERENTIATION FACTORS 15 (GDF-15), AND THEIR USE IN THE TREATMENT OF CANCER CAUSED BY CANCER AND CANCER | |
| HRP20160158T4 (en) | Soluble "heavy-chain only" antibodies | |
| WO2011127412A3 (en) | Soluble human st-2 antibodies and assays | |
| HRP20191697T1 (en) | Binding molecules for bcma and cd3 | |
| MX341958B (en) | Antibodies against human il33r and uses thereof. | |
| JP2013198490A5 (en) | ||
| HK1201279A1 (en) | Antibody and methods for selective inhibition of t-cell responses | |
| MY157532A (en) | A monoclonal antibody to cd44 for use in the treatment of head and neck squamous cell carcinoma | |
| HK1201855A1 (en) | Antibodies and methods of treating cancer | |
| IN2014CN02113A (en) | ||
| WO2012083020A3 (en) | Antibody-linked immuno-sedimentation agent and method of isolating a target from a sample using same | |
| WO2013087857A3 (en) | Antibodies against c. difficile toxins | |
| MY210018A (en) | Monoclonal antibody that binds specifically to gitr |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| KA4Y | Short-term patent lapsed due to non-payment of fees (with right of restoration) | ||
| MM4Y | Short-term patent definitely lapsed due to non-payment of fees |